Disruptive SCYL1 Mutations Underlie a Syndrome Characterized by Recurrent Episodes of Liver Failure, Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia  by Schmidt, Wolfgang M. et al.
REPORT
Disruptive SCYL1 Mutations Underlie a Syndrome
Characterized by Recurrent Episodes of Liver Failure,
Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia
Wolfgang M. Schmidt,1,7 S. Lane Rutledge,2,7 Rebecca Schu¨le,3,4,5,7 Benjamin Mayerhofer,1
Stephan Zu¨chner,5 Eugen Boltshauser,6 and Reginald E. Bittner1,*
Hereditary ataxias comprise a group of genetically heterogeneous disorders characterized by clinically variable cerebellar dysfunction
and accompanied by involvement of other organ systems. Themolecular underpinnings formany of these diseases are widely unknown.
Previously, we discovered the disruption of Scyl1 as the molecular basis of the mouse mutant mdf, which is affected by neurogenic
muscular atrophy, progressive gait ataxia with tremor, cerebellar vermis atrophy, and optic-nerve thinning. Here, we report on three hu-
man individuals, from two unrelated families, who presented with recurrent episodes of acute liver failure in early infancy and are
affected by cerebellar vermis atrophy, ataxia, and peripheral neuropathy. By whole-exome sequencing, compound-heterozygous muta-
tions within SCYL1 were identified in all affected individuals. We further show that in SCYL1-deficient human fibroblasts, the Golgi
apparatus is massively enlarged, which is in line with the concept that SCYL1 regulates Golgi integrity. Thus, our findings define
SCYL1 mutations as the genetic cause of a human hepatocerebellar neuropathy syndrome.Hereditary cerebellar ataxias are genetically heterogeneous
disorders characterized by clinically variable gait distur-
bances and often accompanied by additional neurological
symptoms and involvement of other organs. The molecu-
lar underpinnings of the vast majority of these disorders
still remain widely unknown.1–4 In a previous study, we
uncovered the genetic defect underlying the mdf (muscle
deficient) mouse by identifying a frame-shifting mutation
in Scyl15. Initially, themdfmouse was considered a murine
motor-neuron-disease model, owing to the progressive loss
of motor neurons in the spinal cord and brain stem,
causing severe neurogenic muscular atrophy.6 Our group
refined the mdf phenotype by demonstrating that the
mdfmouse is affected by a complex form of spinocerebellar
ataxia, characterized by progressive gait ataxia, cerebellar
vermis atrophy, Purkinje cell loss, and optic-nerve thin-
ning.5
SCYL1 is highly conserved among eukaryotes and be-
longs to the SCY1-like family of catalytically inactive pro-
tein kinases, harboring an N-terminal serine-threonine
kinase-like domain,7 a centrally located HEAT repeat
domain, and C-terminal protein-interaction motifs.
Recent findings by others have demonstrated that SCYL1
represents an important protein at the interface between
the Golgi apparatus and themembrane traffickingmachin-
ery mediated by coatomer (COPI)-coated vesicles.8–10 Spe-
cifically, it has been shown that SCYL1 exerts a crucial role
in COPI-mediated retrograde protein trafficking by under-
going oligomerization through the HEAT repeats and inter-
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The Americanaddition, SCYL1 is a cytoplasmic component of the nu-
clear tRNA export machinery.11 Together, this suggests
that SCYL1 is involved in vital intracellular transport pro-
cesses, which might provide a basis for understanding the
molecular mechanism underlying disease states caused by
loss of SCYL1.
Here, we report on two families with three individuals
affected by a previously undescribed ataxia syndrome.
Informed consent was obtained from all involved individ-
uals (or their parents), and the institutional ethical com-
mittees of the participating medical centers (University
of Alabama at Birmingham and the University of Miami)
approved the study.
First, we identified two siblings, a young woman (20
years old, F1:II.2) and her brother (16 years old, F2:II.3),
born to unrelated healthy parents of white European
descent with British and German roots (family 1), with a
strikingly similar clinical phenotype (Table 1). Beginning
at the age of 9 months, both siblings presented with recur-
rent episodes of liver failure mainly triggered by fever.
These recurrent and occasionally severe episodes ceased
in mid-childhood. However, both were left with chronic
residual fibrotic liver disease and pronounced hepatomeg-
aly and concomitant splenomegaly (Figure 1). Neurologi-
cally, both siblings had a delay in achieving early motor
milestones. Since early childhood, they developed cere-
bellar dysfunction presenting as gait disturbances
(inability to tandem gait, mild balance difficulties, occa-
sional falling) and intention tremor. Additionally, they
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Table 1. Genetic and Clinical Findings of Individuals with SCYL1 Mutations
Family 1 Family 2
Individual 1 (F1:II.2) Individual 2 (F1:II.3) Individual 3 (F2:II.1)
Age at most recent clinical
examination (years)
20 16 17
Gender female male female
Descent European Cuban
SCYL1 mutation allele 1 c.937delG, p.Val313Cysfs*6 c.1230þ1G>A, p.?
SCYL1 mutation allele 2 c.1509_1510delTG, p.Ala504Profs*15 c.1636C>T, p.Gln546*
Hepatology
No. of recurrent episodes of
liver dysfunction (age at first
episode to age at last episode)
5 (9 months to 11 years) 3 (9 months to 6 years) 3 (18 months to 3 years)
Hepatosplenomegaly þþ þþ þ




Walking independently (months) 17 24 12
Cognition normal mild intellectual disability mild learning disability
Neurogenic stutter (age of onset, years) þ (20) þþ (4) þþ (3)
Cerebellar oculomotor disturbance þ þ saccadic pursuit
Limb ataxia (UL/LL) / / þ/þ
Gait ataxia (onset) þ (early childhood) þ (early childhood) þ (childhood)
Distal weakness LL > UL LL > UL LL > UL
Muscle atrophy LL ¼ UL LL ¼ UL LL ¼ UL
Sensory deficits and symptoms decreased pain perception
(distal LL)
ND intermittent distal paresthesias
(UL and LL)
Electroneurophysiology ND ND axonal PNP
Stretch reflexes decreased (LL) decreased (LL) increased (UL > LL)
Spasticity   þ (UL)
Hip abductor weakness   þ (LL, central pattern)
Tremor intention (cerebellar) intention (cerebellar) action
MRI
Cerebellar vermis atrophy þþ þþ þ
Optic nerve thinning þ þ ND
Abbreviations are as follows: UL, upper limbs; LL, lower limbs; PNP, peripheral neuropathy; ND, not determined; , not present; þ, present (mild); þþ, present
(pronounced).presenting with foot drop, and numbness, indicative of a
hereditary motor and sensory neuropathy. Both individ-
uals are affected by neurogenic stuttering, which is more
pronounced in the male sibling, negatively impacting his
communication skills (Table 1).
Initial MRI scans were performed at ages 9 (F1:II.3) and
13 years (F1:II.2), respectively, and revealed a selective atro-
phy of the cerebellar vermis (Figures 2A–2C), which was
apparently non-progressive over a follow-up period of 7
years. The hemispheres of the cerebellum appeared normal
(Figure 2C). Additionally, thinning of the optic nerves856 The American Journal of Human Genetics 97, 855–861, Decemb(Figure 2D) was depicted on MRI scans performed at ages
16 (F1:II.3) and 20 (F1:II.2), compatible with subclinical
optic atrophy given that both individuals still have well-
preserved visual acuity. In the first MRI, measurements of
the optic nerves were not possible due to artifacts caused
by dental braces.
To unravel the genetic etiology of the cerebellar ataxia
syndrome in this family, we performed whole-exome
sequencing.13–15 DNA libraries were constructed from
one affected individual (F1:II.3), both parents (F1.I.1 and
F1:I.2), and the unaffected sister (F1:II.1) with theer 3, 2015
Figure 1. Hepato- and Splenomegaly Represent Early-Onset
Clinical Findings
Abdominal computed tomography image (coronal reconstruc-
tion) showing significant hepato- and splenomegaly in the male
affected individual (family 1) at age 8 years. The liver (L) was
palpable 9 cm below the right costal margin and the spleen (S)
was palpable 6 cm below the left costal margin.
Figure 2. Selective Atrophy of the Cerebellar Vermis and
Thinning of the Optic Nerve
(A–C) T2 weighted MRI scans from the male affected individual
(F1:II.3) at age 16, revealing selective cerebellar vermis atrophy
with spared hemispheres (and no brain stem or cerebral abnormal-
ities). The signal of the cerebellar white and gray matter appears
normal. Mid-sagittal cut showing upper vermis atrophy with
markedly dilated interfolial fissures (black arrows) and normal
pons (A), axial image (B), and coronal image (C) (note the normal
hemispheres at this level). White arrows in (B) and (C) point to
atrophic vermis.
(D) Retro-bulbar coronal cut from T2 weighted MRI scan from the
same affected individual, showing optic nerve thinning (optic
nerves are indicated by white arrows, the inset shows a close-up
of transverse-cut optic nerve with a horizontal diameter of
1.8 mm). Significant optic nerve thinning as revealed by retro-
bulbar diameter measurements was present in both affected sib-
lings (1.7–1.9 mm, compared to ~3 mm in healthy age-matched
probands12).SureSelect XT2 All Exon V4 kit (Agilent). Sequencing
(100 bp paired-end reads) was performed by GeneDx on
a HiSeq 2000 sequencing system (Illumina). The DNA
sequence was mapped to and analyzed against the refer-
ence human genome (UCSC Genome Browser hg19;
within the targeted coding exons and splice junctions of
known protein-coding RefSeq genes, the average depth-
of-coverage was 119-fold and 97.8% of the target sequence
was covered at least 10-fold). The GeneDx Xome Analyzer
software was used to evaluate sequence changes in the
affected individual in comparison to changes in other
sequenced family members.
Whole-exome variant analysis did not yield pathogenic
variants in any genes with known ataxia associations,
neither in genes currently related to ‘‘hereditary ataxia’’
or in any of the 125 genes associated with ‘‘ataxia’’ in Hu-
man Gene Mutation Database (HGMD) entries. However,
both affected siblings were found to harbor two mutations
within SCYL1 (SCY1-like, kinase-like [MIM: 607982]),
c.937delG (p.Val313Cysfs*6) in exon 7 and c.1509_
1510delTG (p.Ala504Profs*15) in exon 11 (GenBank:
NM_020680.3). Neither mutation is represented in large
reference datasets, such as 1000 Genomes (October 2014
data release, more than 2,500 individuals), the NHLBI
Exome Sequencing Project (ESP) Exome Variant Server
(6,500 exomes), or the Exome Aggregation ConsortiumThe AmericanBrowser (ExAc, January 2015 release, encompassing data
from more than 60,000 unrelated individuals). SCYL1mu-
tations in all members of the family were confirmed by
PCR and conventional DNA sequencing (PCR protocol
and primer sequences are available from the authors on
request).
The existence of two very rare putative null-mutations in
SCYL1, the ortholog of which has been shown to be
mutated in the Scyl1mdf/mdfmouse model,5 provided strong
evidence that disruption of SCYL1might be the molecular
cause of the multisystem disorder in this family. In line
with this assumption, we confirmed that both affected sib-
lings are compound heterozygous for the two mutations,
whereas both parents are carriers of only one or the other
mutation and an unaffected sibling carries neither (Figures
3A–3C).
To determine whether disruptive mutations in SCYL1
are causatively related to an autosomal recessivelyJournal of Human Genetics 97, 855–861, December 3, 2015 857
Figure 3. Compound Heterozygous SCYL1 Mutations in Three
Individuals from Two Unrelated Families
Panels (A)–(C) show family 1 and panels (D)–(F) show family 2.
Pedigrees in (A) and (D) depict segregation of SCYL1 lesions
detected by whole-exome sequencing and confirmed by con-
ventional capillary DNA sequencing (B and C and E and F,
respectively). DNA from the unaffected sister in family 2 (F2:II.2)
was not available for analysis. Biallelic mutations are represented
in red and dark gray. Reference sequences are shown below the
traces from affected individuals, where consequences caused by
the respective mutations (indicated by arrows) are shown in the
second lines. Codon triplets are represented by underlined letters,
exonic residues are shown in capitals, and intronic sequence is
shown in lower case. Mutation positions refer to GenBank tran-
script NM_020680.3.inherited hepatocerebellar ataxia-neuropathy syndrome,
we subsequently queried the Genesis (formerly GEM.app)
database,16 a collaborative web-platform comprising
more than 7,000 whole exomes and 1,200 whole ge-
nomes, including ~5,000 datasets of families with a wide
spectrum of neurological disorders. Whole-exome
sequencing was performed with the SureSelect Human
All Exon 50Mb kit (Agilent) for capture and 120 bp
paired-end sequencing on a HiSeq2000 (Illumina). Data
analysis was performed with the Genesis (GEM.app)
pipeline (the average depth-of-coverage was 77-fold
and 85% of the target sequence was covered at least
10-fold).858 The American Journal of Human Genetics 97, 855–861, DecembWe identified two different formally disruptive SCYL1
mutations in a presently 17-year-old girl (F2:II.1, Table 1)
initially diagnosed with Charcot-Marie-Tooth disease.
The phenotype bore striking similarities to the two siblings
with SCYL1 mutations described above. The girl was born
to non-consanguineous parents with at least three genera-
tions of Cuban family history (family 2). Between the ages
of 18 months and 3 years, she suffered from three episodes
of acute liver failure, each brought about by a febrile infec-
tion, which left hepatosplenomegaly as a residuum. Liver
biopsy performed during one of the acute episodes re-
vealed acute hepatitis with early bridging fibrosis. The first
of these episodes was accompanied by a generalized status
epilepticus and required artificial respiration for almost
three weeks. Although her achievements of motor mile-
stones were reportedly normal, she developed progressive
gait problems at age 3, leading to frequent falling and early
exhaustion, and a progressively debilitating neurogenic
stutter. At age 10, running was barely possible and mark-
edly reduced fine motor coordination was noted. At age
17, a predominant motor peripheral neuropathy, mani-
fested by distally accentuated weakness in the upper and
lower limbs, pronounced amyotrophy of the hands and
feet, and bilateral pes equinus, dominated the clinical pic-
ture. Additionally, mild cerebellar and pyramidal system
involvement was noted and a learning disability suspected,
although not formally tested. Nerve conduction studies
corroborated the diagnosis of a mixed sensorimotor
peripheral neuropathy. At age 13, a subtle atrophy of the
upper cerebellar vermis was noted onMRI (Figure S1). Mea-
surements of optic nerve diameters were not possible for
technical reasons.
The SCYL1 mutations identified in this individual,
namely a splice-site mutation (c.1230þ1G>A [p.?])
affecting the invariable þ1 nucleotide of intron 9 (causing
disruption of correct mRNA splicing by inducing skipping
of exon 9, which encodes part of the HEAT repeat domain,
Figure S2) and a premature termination mutation
(c.1636C>T [p. Gln546*]) in exon 12, are predictably dele-
terious. Neither mutation is referred to in the reference da-
tabases mentioned above. Whereas the mother (F2:I.1) is
heterozygous for the splice-site mutation, the father
(F2:I.2) is heterozygous for the nonsense mutation, indi-
cating compound heterozygosity (Figures 3D–3F).
In the next step, we probed dermal fibroblasts of the
affected individuals and their parents (family 1) to deter-
mine the amounts of SCYL1 by using two antibodies
directed against the C and N termini of SCYL1.5 In contrast
to the normal amount of SCYL1 detected in fibroblasts
from both parents, there was a complete loss of SCYL1 in
fibroblasts from both affected individuals, as revealed by
western blotting (Figure 4A) and immunofluorescence ex-
periments (Figures 4B and 4C).
SCYL1-knockdown in vitro experiments in HeLa cells
suggested a role of SCYL1 in context with the integrity of
the Golgi apparatus.8,9 Therefore, we measured the surface
area of the Golgi in dermal fibroblasts derived fromer 3, 2015
Figure 4. SCYL1-Null Mutations Lead to
Complete Lack of SCYL1 in Cultured Skin
Fibroblasts
(A) Complete loss of SCYL1 in protein ex-
tracts from fibroblasts from both affected
siblings (F1:II.2 and F1:II.3), in contrast to
fibroblasts from their parents (F1:I.1 and
F1:I.2), with bothN-terminal (upper panel)
and C-terminal antibodies (lower panel).
Extracts prepared from human WI-38 fetal
lung fibroblasts (Co) and murine fibro-
blasts from mdf (Scyl1mdf/mdf) and wild-
type (Scyl1þ/þ) as well as heterozygous
(Scyl1þ/mdf) littermates were used as con-
trols. MW; molecular weight marker
(kDa). Arrowheads indicate full-length
SCYL1 (~105 kDa band).
(B and C) Absent SCYL1 immunoreactivity
(N-terminal antibody, goat anti-rabbit sec-
ondary antibody conjugated with Alexa
Fluor 594, red fluorescence) in skin fibro-
blasts from female affected individual
F1:II.2 (B) in comparison to a predomi-
nantly perinuclear vesicular SCYL1-stain-
ing pattern (white arrows) obtained in
fibroblasts from her mother, F1:I.1 (C).
The F-actin cytoskeleton is visualized by
Phalloidin Atto 488 (green fluorescence)
and nuclei are depicted with DAPI (blue).affected individuals and their parents and found the Golgi
to be massively enlarged in SCYL1-negative cells (Figures
5A–5C). These data indicate that SCYL1 is indeed a regu-
lator of Golgi morphology not only in HeLa cells in knock-
down experiments,9 but also in primary human fibroblasts
affected by naturally occurring, disruptive mutations of
SCYL1.
The clinical manifestations of the disease in the individ-
uals described in this study overlap to a large extent with
the phenotype of the Scyl1mdf/mdf mouse model. Cerebellar
ataxia accompanied by cerebellar vermis atrophy, motor-
predominant peripheral neuropathy, and optic-nerve thin-
ning are consistent neurological features in both mice and
humans. Whereas peripheral neuropathy and distal
muscular atrophy predominate in individual F2:II.1, cere-
bellar ataxia represents the most striking phenotype in
both siblings in family 1 (F1:II.2 and F1:II.3). However,
neurogenic stuttering, optic-nerve thinning and upper
motor neuron dysfunction suggest a more widespread
SCYL1-associated clinical and pathologic phenotype.
Intriguingly, although all three affected individuals re-
ported here presented with severe recurrent episodes of
acute liver failure in infancy, no such episodes or
corresponding phenotypes have been observed in the
Scyl1mdf/mdf mouse so far, warranting more in-depth inves-
tigations regarding this in the mouse model.
Collectively, our data provide compelling evidence that
disruptive mutations in SCYL1 cause a syndrome charac-
terized by early-onset episodes of acute liver failure,
cerebellar ataxia, and peripheral motor and sensory neu-
ropathy in humans. It is probable that the SCYL1 muta-
tions identified here represent the more severe end of theThe Americanmutational landscape. Other lesions, such as missense mu-
tations, which do not fully abrogate SCYL1 function,
might be associated with a variable clinical picture. The
description of other individuals with SCYL1 mutations
has to be awaited, which will allow the capture of a foresee-
ably-wide clinical spectrum of manifestations. Our find-
ings add SCYL1 to a list of several other genes implicated
in disorders involving the cerebellum, whose gene prod-
ucts are implicated in the Golgi network.17–19
Several causes for hereditary infantile liver failure are
currently known. Interestingly, mutations in MARS
(MIM: 156560) and LARS (MIM: 151350), both encoding
tRNA synthetases, are associated with multisystem mani-
festations involving transient infantile hepatopathy.20,21
Although speculative, the functional role of SCYL1 in nu-
clear-cytoplasmic tRNA transport might therefore be
related to the molecular mechanism behind the transient
liver failure shared by all three individuals with SCYL1mu-
tations in this study. Notably, mutations in NBAS (MIM:
608025), encoding a protein that is apparently involved
in retrograde transport from the Golgi to the ER, were
recently shown to cause early-onset recurrent acute liver
failure (infantile liver failure syndrome 2, ILFS2 [MIM:
616483])22 or a multisystem disorder involving infantile
liver failure.23 Because SCYL1 was also shown to be
involved in a similar Golgi-ER-pathway,10 it is tempting
to speculate that dysfunction of the Golgi-ER transport
function might represent a common pathogenic mecha-
nism, which underlies severe recurrent episodes of acute
liver failure in infancy. These parallels warrant further
studies to investigate how loss of SCYL1 can cause liver
failure.Journal of Human Genetics 97, 855–861, December 3, 2015 859
Figure 5. Absence of SCYL1 Leads to
Enlargement of the Golgi Apparatus in
Human Fibroblasts
By immunofluorescence, the Golgi
network appeared enlarged in the skin fi-
broblasts from the male affected individ-
ual, F1:II.3, (A) when compared to the
Golgi staining in his father’s, F1:I.2, fibro-
blasts (B). Anti-TGN46 (also known as
TGOLN2, a trans-Golgi-network protein)
antibody (Sigma-Aldrich; T7576) is shown
as red fluorescence. The F-actin cytoskel-
eton is visualized by Phalloidin Atto 488
(green fluorescence) and nuclei are de-
picted with DAPI (blue). Morphometric
analysis revealed enlargement of Golgi ap-
paratuses in SCYL1-negative fibroblasts
(C). Shown as a percentage of total cell
size; p < 5e-14, Mann-Whitney-Wilcoxon
test.Once more, this study demonstrates that molecular ge-
netics and pre-clinical research onmousemodels is capable
of propelling the identification and understanding of the
corresponding human disease24,25 and strongly argues for
an unbiased exome-wide strategy in the molecular diag-
nosis of individuals affected by rare inherited disorders.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ajhg.2015.10.011.Acknowledgments
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